製品: RBM15 Antibody
カタログ: DF12061
タンパク質の説明: Rabbit polyclonal antibody to RBM15
アプリケーション: WB IHC
Cited expt.: WB, IHC
反応性: Human, Mouse, Rat
予測: Pig, Bovine, Horse, Sheep, Rabbit, Dog
分子量: 100-107 kDa; 107kD(Calculated).
ユニプロット: Q96T37
RRID: AB_2844866

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%)
クローナリティ:
Polyclonal
特異性:
RBM15 Antibody detects endogenous levels of total RBM15.
RRID:
AB_2844866
引用形式: Affinity Biosciences Cat# DF12061, RRID:AB_2844866.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

One twenty two protein; One-twenty two protein 1; OTT; OTT1; Putative RNA-binding protein 15; RBM15; RBM15_HUMAN; RNA binding motif protein 15; RNA-binding motif protein 15;

免疫原

免疫原:

A synthesized peptide derived from human RBM15, corresponding to a region within N-terminal amino acids.

Uniprot:
遺伝子(ID):
タンパク質配列:
MRTAGRDPVPRRSPRWRRAVPLCETSAGRRVTQLRGDDLRRPATMKGKERSPVKAKRSRGGEDSTSRGERSKKLGGSGGSNGSSSGKTDSGGGSRRSLHLDKSSSRGGSREYDTGGGSSSSRLHSYSSPSTKNSSGGGESRSSSRGGGGESRSSGAASSAPGGGDGAEYKTLKISELGSQLSDEAVEDGLFHEFKRFGDVSVKISHLSGSGSGDERVAFVNFRRPEDARAAKHARGRLVLYDRPLKIEAVYVSRRRSRSPLDKDTYPPSASVVGASVGGHRHPPGGGGGQRSLSPGGAALGYRDYRLQQLALGRLPPPPPPPLPRDLERERDYPFYERVRPAYSLEPRVGAGAGAAPFREVDEISPEDDQRANRTLFLGNLDITVTESDLRRAFDRFGVITEVDIKRPSRGQTSTYGFLKFENLDMSHRAKLAMSGKIIIRNPIKIGYGKATPTTRLWVGGLGPWVPLAALAREFDRFGTIRTIDYRKGDSWAYIQYESLDAAHAAWTHMRGFPLGGPDRRLRVDFADTEHRYQQQYLQPLPLTHYELVTDAFGHRAPDPLRGARDRTPPLLYRDRDRDLYPDSDWVPPPPPVRERSTRTAATSVPAYEPLDSLDRRRDGWSLDRDRGDRDLPSSRDQPRKRRLPEESGGRHLDRSPESDRPRKRHCAPSPDRSPELSSSRDRYNSDNDRSSRLLLERPSPIRDRRGSLEKSQGDKRDRKNSASAERDRKHRTTAPTEGKSPLKKEDRSDGSAPSTSTASSKLKSPSQKQDGGTAPVASASPKLCLAWQGMLLLKNSNFPSNMHLLQGDLQVASSLLVEGSTGGKVAQLKITQRLRLDQPKLDEVTRRIKVAGPNGYAILLAVPGSSDSRSSSSSAASDTATSTQRPLRNLVSYLKQKQAAGVISLPVGGNKDKENTGVLHAFPPCEFSQQFLDSPAKALAKSEEDYLVMIIVRGFGFQIGVRYENKKRENLALTLL

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

研究背景

機能:

RNA-binding protein that acts as a key regulator of N6-methyladenosine (m6A) methylation of RNAs, thereby regulating different processes, such as hematopoietic cell homeostasis, alternative splicing of mRNAs and X chromosome inactivation mediated by Xist RNA. Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (By similarity). Plays a key role in m6A methylation, possibly by binding target RNAs and recruiting the WMM complex. Involved in random X inactivation mediated by Xist RNA: acts by binding Xist RNA and recruiting the WMM complex, which mediates m6A methylation, leading to target YTHDC1 reader on Xist RNA and promoting transcription repression activity of Xist. Required for the development of multiple tissues, such as the maintenance of the homeostasis of long-term hematopoietic stem cells and for megakaryocyte (MK) and B-cell differentiation (By similarity). Regulates megakaryocyte differentiation by regulating alternative splicing of genes important for megakaryocyte differentiation; probably regulates alternative splicing via m6A regulation. Required for placental vascular branching morphogenesis and embryonic development of the heart and spleen (By similarity). Acts as a regulator of thrombopoietin response in hematopoietic stem cells by regulating alternative splicing of MPL (By similarity). May also function as an mRNA export factor, stimulating export and expression of RTE-containing mRNAs which are present in many retrotransposons that require to be exported prior to splicing. High affinity binding of pre-mRNA to RBM15 may allow targeting of the mRNP to the export helicase DBP5 in a manner that is independent of splicing-mediated NXF1 deposition, resulting in export prior to splicing. May be implicated in HOX gene regulation.

PTMs:

Methylated at Arg-578 by PRMT1, leading to promote ubiquitination by CNOT4 and subsequent degradation by the proteasome.

Ubiquitinated by CNOT4 following methylation at Arg-578 by PRMT1.

細胞の位置付け:

Nucleus speckle. Nucleus>Nucleoplasm. Nucleus envelope. Nucleus membrane>Peripheral membrane protein.
Note: Colocalizes at the nuclear pore with DBP5 and NXF1.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
タンパク質ファミリー:

Belongs to the RRM Spen family.

参考文献

1). Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy. Frontiers in Immunology, 2022 (PubMed: 36389678) [IF=5.7]

Application: IHC    Species: Human    Sample:

Figure 10 Representative immunohistochemical staining of RBM15, KIAA1429, FTO in benign thyroid nodule tissue and thyroid cancer tissue. (A) Immunohistochemical image of FTO in thyroid cancer tissue. (B) Immunohistochemical image of FTO in benign thyroid nodule tissue.(C) Immunohistochemical image of RBM15 in PTC tissue. (D) Immunohistochemical staining image of RBM15 in benign thyroid nodule tissue. (E) Immunohistochemical image of KIAA1429 in PTC tissue. (F) Immunohistochemical image of KIAA1429 in benign thyroid nodule tissue.

2). RBM15-mediated m6A modification of XPR1 promotes the malignant progression of lung adenocarcinoma. Naunyn-Schmiedeberg's archives of pharmacology, 2025 (PubMed: 39928150) [IF=3.1]

Application: WB    Species: human    Sample: LUAD cells

Fig. 3 RBM15 stabilized XPR1 mRNA expression through m6A modification in LUAD cells. (A and B) The dual-luciferase reporter assay and MeRIP assay were performed to identify the association between RBM15 and XPR1. (C) The actinomycin D assay was performed to analyze the effect of RBM15 silencing on the stability of XPR1 mRNA in both A549 and PC-9 cells. (D) The effects of RBM15 silencing on RBM15 and XPR1 protein expression were analyzed by western blotting assay. (E) RBM15 expression was analyzed through the TCGA database in LUAD tissues and normal lung tissues. (F) The IHC assay was used to analyze RBM15 protein expression in clinical LUAD tissues and normal lung tissues. (G) RBM15 mRNA expression was quantified by qRT-PCR in clinical LUAD tissues and normal lung tissues. (H and I) The western blotting assay was used to analyze RBM15 protein expression in clinical LUAD tissues, normal lung tissues, 16HBE cells, A549 cells and PC-9 cells. (J and K) The correlation analysis of RBM15 and XPR1 in LUAD tissues. **P 

Application: IHC    Species: Mouse    Sample:

Fig. 5 RBM15 silencing delayed tumor growth by regulating XPR1 in vivo. A549 cells were injected subcutaneously into the flanks of the mice following intratumor injection with sh-RBM15, XPR1, sh-NC and/or vector. Tumor volume was analyzed every 1 week (A), and the tumors were harvested after 4 weeks for tumor weight analysis (B) and protein expression analysis of RBM15, XPR1 and ki-67 (C). **P 

3). SILENCING M 6 A READER YTHDC1 REDUCES INFLAMMATORY RESPONSE IN SEPSIS-INDUCED CARDIOMYOPATHY BY INHIBITING SERPINA3N EXPRESSION. Shock (Augusta, Ga.), 2023 (PubMed: 36877222) [IF=2.7]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.